Lehigh Valley Topper Cancer Institute has been selected as a clinical trial site for Michigan-based Strata Oncology Inc.
The institute joins Strata Oncology Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, along with the University of Michigan Health Rogel Cancer Center in the Strata Sentinel trial.
The trial is a prospective, observational study of the StrataMRD minimal residual disease test that has the potential to shift cancer care, bringing the use of biomarker-matched precision therapies to earlier stages of the disease, Strata Oncology said.
“At Lehigh Valley Topper Cancer Institute, we are continuously working to improve cancer care, including partnering with innovators to bring the latest technology to the patients we serve,” said Dr. Suresh Nair, physician in chief of the Lehigh Valley Topper Cancer Institute. “With the Strata Sentinel trial, we aim to demonstrate the utility of detecting recurrence as soon as possible using the ctDNA-based StrataMRD test.
“We will also evaluate the clinical benefit of treating patients with micrometastatic disease, including with biomarker-matched therapies chosen based on the extended treatment selection data provided by Strata Oncology platform,” Nair said.
“The Strata Sentinel trial is a key piece of our strategy of developing integrated solutions to enable smarter and earlier cancer treatment,” said Dan Rhodes, PhD, co-founder and CEO, Strata Oncology. “We are grateful to add Lehigh Valley Topper Cancer Institute and the University of Michigan Health Rogel Cancer Center to our growing list of partners that we are working with to not only collect clinical validation and utility data, but also to learn together to create the sustainable, scalable systems necessary to deliver the best possible treatment to every patient with cancer.”